Recent Updates
Recently added Catalysts

627

Phase 2

Ulcerative Colitis (UC) | Small molecule | Gastrointestinal |Sunshine Biopharma Inc.|Last Updated: Apr 2, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment288
FDA Designations
No designations recorded
Clinical trial landscape

627 · 2 trials · 2 indications

Phase 2 1Phase 1 1
NCT07507513The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UCUlcerative Colitis (UC)
NOT YET_RECRUITING288 Analytics
PHASE2NOT YET_RECRUITING
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
Ulcerative Colitis (UC)
NCT07507513288
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of participants with Adverse Events
During the 36-week study period
Secondary Endpoints
Clinical remission based on Mayo Score (MMS)
Week 14
Clinical response based on Mayo Score (MMS)
Week 14
Endoscopic improvement
Week 14
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Group M1EXPERIMENTALdose level 1 of 627
Group M2EXPERIMENTALdose level 2 of 627
Group M3EXPERIMENTALdose level 3 of 627
Group M4EXPERIMENTALdose level 4 of 627
Group AEXPERIMENTAL627 Dose A subcutaneous (SC) injection.
Group BEXPERIMENTAL627 Dose B subcutaneous (SC) injection.
PlaceboPLACEBO_COMPARATORPlacebo subcutaneous (SC) injection.
Group CEXPERIMENTAL627 subcutaneous (SC) injection.
627EXPERIMENTAL -
Interventions
NameTypeDescription
627DRUG627 subcutaneous (SC) injection.
PlaceboDRUGPlacebo subcutaneous (SC) injection.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Able to understand and comply with the requirements of the study protocol, and sign the written informed consent form (ICF). 2. Male or female subjects aged 18-75 years old when signing the ICF. 3. Subjects must have been diagnosed with UC for at least 3 months prior to rando...

Countries:China
Unlock Eligibility Criteria
Competitive Landscape -Ulcerative Colitis 92 trials (matched to "Ulcerative Colitis (UC)")
CompanyTickerTrialsLead PhaseDrugs
Sanofi SA Sponsored ADRSNY8PHASE3Duvakitug
Eli Lilly and CompanyLLY8PHASE3Mirikizumab
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK11PHASE3Vedolizumab
Johnson & JohnsonJNJ13PHASE3Ustekinumab
AbbVie, Inc.ABBV14PHASE3Upadacitinib
Merck & Co., Inc.MRK3PHASE3Tulisokibart
Pfizer Inc.PFE8PHASE3Etrasimod
Gilead Sciences, Inc.GILD3PHASE3Filgotinib
Abivax SA Sponsored ADRABVX2PHASE3ABX464
Bristol-Myers Squibb CompanyBMY5PHASE2Ozanimod
Spyre Therapeutics, IncSYRE1PHASE2SPY001, SPY002, SPY003
AnaptysBio, Inc.ANAB1PHASE2Rosnilimab
Palatin Technologies, Inc.PTN1PHASE2PL8177
GSK plc Sponsored ADRGSK1PHASE1GSK4528287
Xencor, Inc.XNCR1PHASE1XmAb942
Sunshine Biopharma IncorporatedSBFM1PHASE2627
Amgen Inc.AMGN1N/AUndisclosed
TScan Therapeutics, Inc.TCRX1 - Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJul 5, 2026NCT07065136primaryCompletionDate: changed
LOWJul 5, 2026NCT07507513primaryCompletionDate: changed
LOWJul 5, 2026NCT07065136primaryCompletionDate: changed
LOWJul 5, 2026NCT07507513primaryCompletionDate: changed
LOWJul 5, 2026NCT07065136primaryCompletionDate: changed
LOWJul 5, 2026NCT07507513primaryCompletionDate: changed
LOWMay 24, 2026NCT07065136studyFirstPostDate: changed
LOWMay 24, 2026NCT07507513studyFirstPostDate: changed